wegovy tirzepatide or semaglutide Outperforms in Reducing Major Adverse Cardiovascular Events Semaglutide vs Tirzepatide: Key Differences
Description
Results from these clinical studies demonstrated significant improvements in glycaemic control, as indicated by notable reductions in glycated haemoglobin levels (-1.87% to -2.59%, -20 to -28 mmol/mol)
Why the warning
Formulations *Vitamin B12 as cyanocobalamin
The early data from obesity trials shows favorable trends in cardiovascular risk factors, but definitive outcome data remains forthcoming
Others are developing medicines that are longer-acting than those from Novo Nordisk and Lilly
